Valuation: IntoCell, Inc.

Market Cap 333B 239M 205M 192M 176M 331M 22.88B 336M 2.26B 886M 11.47B 899M 879M 37.93B P/E 2024 *
-
P/E 2025 -77.1x
Enterprise Value 312B 225M 193M 180M 165M 310M 21.46B 315M 2.12B 831M 10.76B 843M 825M 35.59B EV / Sales 2024 *
-
EV / Sales 2025 365,559,272x
Free-Float
78.73%
Yield 2024 *
-
Yield 2025 -
1 day-2.39%
1 week-4.22%
Current month+26.39%
1 month-7.05%
3 months-32.73%
6 months-60.37%
Current year-64.37%
1 week 20,050
Extreme 20050
22,850
1 month 13,050
Extreme 13050
23,500
Current year 13,050
Extreme 13050
63,500
1 year 13,050
Extreme 13050
74,900
3 years 13,050
Extreme 13050
74,900
5 years 13,050
Extreme 13050
74,900
10 years 13,050
Extreme 13050
74,900
Manager TitleAgeSince
Chief Executive Officer 66 01/04/2015
Director of Finance/CFO 69 01/06/2019
Chief Tech/Sci/R&D Officer 58 01/04/2021
Director TitleAgeSince
Director/Board Member 66 01/04/2015
Director/Board Member 58 01/04/2021
Director/Board Member 65 01/04/2021
Date Insider Type Main position Quantity % Market Cap.
15/7/25 Buy

Founder

10,000 0.0674%
15/7/25 Buy

Founder

26,000 0.1751%
28/5/25 Free 40,400 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.39%-4.22%-20.12% - 221M
+0.21%+1.57%+1.68%+23.81% 50.5B
-1.31%+4.58%+487.47%+624.71% 46.01B
-0.54%+4.96%+20.59%+95.21% 42.85B
+0.42%+3.13%+29.60%+16.50% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
-0.89%+1.89%+31.62%+143.62% 16.98B
-0.62%+1.63% - - 17.05B
+1.42%+2.11%+4.01%+33.15% 14.3B
-1.05%+1.98%+82.99%+45.80% 13.84B
Average -0.52%+1.39%+72.86%+128.85% 27.48B
Weighted average by Cap. -0.36%+2.37%+104.44%+154.48%

Financials

2024 2025
Net sales 2.91K 2.09 1.79 1.67 1.54 2.89 199.72 2.94 19.75 7.73 100.17 7.85 7.68 331.18 2.3K 1.65 1.42 1.32 1.22 2.29 158.06 2.32 15.63 6.12 79.27 6.21 6.07 262.11
Net income -9.91B -7.13M -6.12M -5.71M -5.24M -9.85M -681M -10.02M -67.39M -26.39M -342M -26.77M -26.19M -1.13B -10.6B -7.63M -6.54M -6.11M -5.6M -10.54M -729M -10.71M -72.08M -28.23M -366M -28.64M -28.01M -1.21B
Net Debt -2.15B -1.54M -1.32M -1.24M -1.13M -2.13M -148M -2.17M -14.59M -5.71M -73.99M -5.8M -5.67M -245M -20.59B -14.81M -12.7M -11.86M -10.88M -20.46M -1.42B -20.8M -140M -54.8M -710M -55.6M -54.39M -2.35B
Logo IntoCell, Inc.
IntoCell Inc is a Korea-based company principally engaged in the development of antibody-drug conjugate (ADC) platform technology. The Company mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.
Employees
-
Date Price Change Volume
19/08/26 ₩20,450.00 -2.39% 47,031
18/08/26 ₩20,950.00 -5.84% 54,208
14/08/26 ₩22,250.00 +2.06% 40,005
13/08/26 ₩21,800.00 +2.11% 40,824
12/08/26 ₩21,350.00 +0.71% 36,712

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A287840 Stock